Results 61 to 70 of about 110,790 (277)

Nanoparticulate matter exposure results in neuroinflammatory changes in the corpus callosum.

PLoS ONE, 2018
Epidemiological studies have established an association between air pollution particulate matter exposure (PM2.5) and neurocognitive decline. Experimental data suggest that microglia play an essential role in air pollution PM-induced neuroinflammation ...
Robin Babadjouni, Arati Patel, Qinghai Liu, Kristina Shkirkova, Krista Lamorie-Foote, Michelle Connor, Drew M Hodis, Hank Cheng, Constantinos Sioutas, Todd E Morgan, Caleb E Finch, William J Mack   +11 more
doaj   +1 more source

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2022
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction.
Raymond S.M. Wong
doaj   +1 more source

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Complement system biomarkers in first episode psychosis [PDF]

, 2019
Several lines of evidence implicate immunological/inflammatory factors in development of schizophrenia. Complement is a key driver of inflammation, and complement dysregulation causes pathology in many diseases.
Di Forti, Marta, Gaughran, Fiona, Kopczynska, Maja, Mondelli, Valeria, Morgan, B. Paul, Murray, Robin, O'Donovan, Michael, Touchard, Samuel, Zelek, Wioleta   +8 more
core   +2 more sources

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species

Frontiers in Immunology, 2020
Better understanding of roles of complement in pathology has fuelled an explosion of interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) eculizumab, the first of the new wave of complement blocking drugs, was FDA ...
Wioleta M. Zelek, B. Paul Morgan
doaj   +1 more source

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

Frontiers in Pharmacology, 2022
Hemolytic uremic syndrome (HUS) is a rare life-threatening disease of unrestrained complement system dysregulation, microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in genetically predisposed individuals.
Valentina Fanny Leone, Amantia Imeraj, Sara Gastoldi, Caterina Mele, Lucia Liguori, Carmelita Condemi, Piero Ruggenenti, Giuseppe Remuzzi, Camillo Carrara   +8 more
doaj   +1 more source

An intracellular self protein synthesized in macrophages is presented but fails to induce tolerance [PDF]

, 2017
Mice deficient for the fifth component of murine complement (C5), unlike normal mice, do not possess the secreted form of C5 in their body fluids and can be readily immunized to serum-derived normal C5.
Lin, Rong Hwa, Stockinger, Brigitta
core  

Targeting Complement C5 in Atypical Hemolytic Uremic Syndrome [PDF]

Journal of the American Society of Nephrology, 2011
Hemolytic uremic syndrome (HUS) is defined as the combination of microangiopathic hemolytic anemia (MAHA), acute renal failure, and thrombocytopenia. It occurs most often during outbreaks of diarrheal food poisoning with enteropathogenic strains of Escherichia coli such as O157:H7 and others ...
openaire   +2 more sources

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source